Crovalimab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sickle Cell Disease With Vaso-Occlusive Crisis. According to GlobalData, Phase II drugs for Sickle Cell Disease With Vaso-Occlusive Crisis have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Crovalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Crovalimab (RO-7112689, RG-6107, SKY-59) is under development for the treatment of vaso-occlusive crisis associated with sickle cell disease, paroxysmal nocturnal hemoglobinuria, lupus nephritis and atypical hemolytic uremic syndrome (aHUS). The drug candidate is administered through the intravenous and subcutaneous route as a solution. The drug candidate is a monoclonal antibody which acts by targeting C5 which is developed based on recycling antibody technology. It is a new molecular entity (NME).
It was also under development for the treatment of Guillain-Barre syndrome.
Chugai Pharmaceutical overview
Chugai Pharmaceutical (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd, is focused on the research, development, commercialization, manufacturing, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
For a complete picture of Crovalimab’s drug-specific PTSR and LoA scores, buy the report here.